⌕
Bio-Rad Laboratories · BIO · NYSE
Tenet 47 · Mixed
Compare
$360.26−1.67%At closeTenet 47 · Mixed
$360.26−6.10 (−1.67%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Bio-Rad Laboratories (BIO) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice

28 figures withheld by our checks. Each blank figure names its reason.

57
VALUE
Fairly priced
in line with its peers
50
QUALITY
Decent
mid-pack profitability
52
HEALTH
Stable
manageable balance sheet
28
GROWTH
FCF only
growth rates not measurable; scored on FCF margin alone

A decent business at a fair price: value 57, quality 50, health 52, growth 28, each a percentile within Healthcare.

track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own 10-year record (context, not scored)hover any metric for its formula
57th pctilein line with its peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.0.5%3rd pctileown record too shortFiscal year to Dec 31, 2025
P/E12.788th pctileown record too shortFiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/B1.393rd pctileown record too shortFiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/FCF25.945th pctileown record too shortFiscal year to Dec 31, 2025
EV / EBITDA—Not reported in the company's filings for this period.
52nd pctilemanageable balance sheet
Current ratio5.6271st pctileFiscal year to Dec 31, 2025
Quick ratio(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.3.8765th pctileFiscal year to Dec 31, 2025
Net debt / EBITDA(Total debt − cash) ÷ EBITDA—Not meaningful: EBITDA is zero or negative.
Interest coverage1.0×12th pctileFiscal year to Dec 31, 2025
Debt / equity0.1659th pctileFiscal year to Dec 31, 2025
50th pctilemid-pack profitability
ROIC0%49th pctileFiscal year to Dec 31, 2025
ROE11%68th pctileFiscal year to Dec 31, 2025
Gross margin51.9%28th pctileFiscal year to Dec 31, 2025
Net margin29.4%94th pctileFiscal year to Dec 31, 2025
Income quality (CFO/NI)0.70×8th pctileFiscal year to Dec 31, 2025
Piotroski F5 / 953rd pctileown record too shortFiscal year to Dec 31, 2025
Altman Z3.552nd pctileown record too shortFiscal year to Dec 31, 2025
28th pctilegrowth rates not measurable; scored on FCF margin alone
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin14.5%70th pctileFiscal year to Dec 31, 2025
the receipts behind the numbers above
Greenblatt earnings yield0.5%EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC0%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage1.0× EBIT ÷ interest expense, ranked within sector peers.
Percentiles computed nightly against 340 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value sits in the company's own ten-year annual record, shown for context and never blended into the score. Computed Nov 16, 2026 · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.